TICKERNERD
Menu
KAPAKAPAHealthcare · Biotechnology

KAPA Stock Forecast: Kairos Pharma Ltd. Price Predictions for 2026-2027

Last close, 15 Sept 2026
$1.85
+0.54% on the day

The 2 Wall Street analysts covering Kairos Pharma Ltd. hold a median 12-month price target of $49 — +2548.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 14 Sept 2026 — in the lower half.

Market cap
$6.0M
Ticker Nerd rank
40 / 100
Median analyst target
$49
Analysts covering
2
Revenue$0.0
Operating income−$1.4M
Net income−$1.4M
Free cash flow−$1.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.5%
1M
−22.5%
YTD
−62.8%
1Y
−83.3%
From 52W high
−84.3%
From 52W low
+17.1%
$2
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KAPA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kairos Pharma Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
40 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
95
Accruals
78
Growth
59
Revisions
53
Volatility
39
Issuance
36
Quality
32
Value
26
Momentum
7

Size (95): Smaller than most of the companies we track.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KAPA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KAPA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26KAPAHigh $84Median $49Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $14Median $49High $84

The green dot is the last close — the median target sits +2548.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Nov 2025D. Boral CapitalMaintainsBuy—
4 Nov 2025D. Boral CapitalMaintainsBuy—
20 Oct 2025D. Boral CapitalMaintainsBuy—
7 Oct 2025D. Boral CapitalMaintainsBuy—
19 Sept 2025D. Boral CapitalMaintainsBuy—
16 July 2025D. Boral CapitalMaintainsBuy—
4 June 2025D. Boral CapitalMaintainsBuy—
17 Apr 2025D. Boral CapitalMaintainsBuy—
3 Apr 2025HC Wainwright & Co.InitiatesBuy—
31 Mar 2025D. Boral CapitalMaintainsBuy—
27 Mar 2025Maxim GroupInitiatesBuy—
20 Mar 2025D. Boral CapitalMaintainsBuy—
26 Feb 2025D. Boral CapitalMaintainsBuy—
18 Feb 2025D. Boral CapitalMaintainsBuy—
12 Feb 2025D. Boral CapitalMaintainsBuy—
22 Jan 2025D. Boral CapitalMaintainsBuy—
14 Nov 2024D. Boral CapitalMaintainsBuy—
14 Oct 2024EF HuttonInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KAPA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KAPA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 15 Sept 2026, Kairos Pharma Ltd. returned −83.3% against +16.4% for the S&P 500, dividends included.

KAPA vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Oct 25Jan 26Apr 26Jul 26KAPAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KAPA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Kairos Pharma Ltd. (KAPA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.9×

Cheaper than 91% of US stocks

Price / sales
—
Price / book
1.3×

Cheaper than 64% of US stocks

EV / EBITDA
−0.6×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−114.0%

Higher than 12% of US stocks

Return on assets
−66.9%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kairos Pharma Ltd. (KAPA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kairos Pharma Ltd. has a market value of $6.0M and an enterprise value of $3.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$5.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$4.0M.

  • Shares outstanding: 21.4M.

  • Trailing P/E: −5.9×; forward P/E: −0.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Kairos Pharma Ltd. employs 1 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

KAPA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KAPAKairos Pharma Ltd.$6.0M
40
CDIOCardio Diagnostics Holdings, Inc.$6.1M
20
CLGNCollPlant Biotechnologies Ltd.$6.6M
34
LEXXLexaria Bioscience Corp.$5.9M
25
ENVBEnveric Biosciences, Inc.$6.6M
17
CELZCreative Medical Technology Holdings, Inc.$5.8M
23
AIMAIM ImmunoTech, Inc.$6.8M
18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kairos Pharma Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KAPA news & analysis

Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Business Wire · 9 Sept 2026neutral

Kairos Pharma announced that CEO and Chairman John Yu, MD, will present a corporate overview in person at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026 at the Lotte New York Palace Hotel. Yu's presentation is set for September 14, 2026 at 4:00 PM Eastern Time.

Why it matters — A KAPA watcher would care because the company's presentation at a major investment conference offers visibility and an opportunity to communicate its corporate overview to the investment community.

Kairos Pharma Announces 1-for-7 Reverse Stock Split

Business Wire · 21 Aug 2026neutral

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced a 1-for-7 reverse stock split of its outstanding common shares. The split is expected to become effective on September 1, 2026 at 12:01 a.m. ET, with shares expected to begin trading on the NYSE American on a split-adjusted basis at that time.

Why it matters — A reverse stock split will consolidate Kairos Pharma's outstanding shares, changing its share count and per-share price, which matters to shareholders tracking the company's capital structure.

FAQ

Frequently asked questions about KAPA stock

What is the KAPA stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Kairos Pharma Ltd. have a median 12-month price target of $49, with estimates ranging from $14 to $84. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KAPA stock a buy right now?

Of the 2 analysts covering Kairos Pharma Ltd., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kairos Pharma Ltd. 40 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KAPA?

As at 14 Sept 2026, Kairos Pharma Ltd. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

Will KAPA stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +2548.8% from the last close, and Ticker Nerd's factor model ranks Kairos Pharma Ltd. 40 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KAPA stock forecast for 2030?

No analyst covering Kairos Pharma Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KAPA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $84 over the next 12 months.

How has KAPA stock performed over the past year?

Kairos Pharma Ltd. returned -83.3% over the 12 months to 15 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kairos Pharma Ltd. do?

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics that address immune suppression and drug resistance.

What is the latest news on KAPA?

The most recent item we track (Business Wire, 9 Sept 2026): "Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference". Kairos Pharma announced that CEO and Chairman John Yu, MD, will present a corporate overview in person at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026 at the Lotte New York Palace Hotel. Yu's presentation is set for September 14, 2026 at 4:00 PM Eastern Time.

Company

About Kairos Pharma Ltd.

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics that address immune suppression and drug resistance. The company’s current portfolio centers on oncology candidates such as antibodies and small molecules designed to support immune function and target difficult-to-treat cancers, including prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma Ltd. also works on immunotherapy and cell therapy approaches, reflecting its emphasis on mechanisms that may help improve treatment response in cancer patients. Based in Los Angeles, California, the company operates in the biotechnology and pharmaceuticals sector, where it contributes to the development of experimental treatments intended for use in specialized oncology settings.

CEO Dr. John S. Yu M.D., Ph.D. · 1 employees · United States · https://kairospharma.com